Cohort CNC-PPNAD will be investigated with clinical, genetic, biological and imaging work-up every year during 3 years. Cohort L-MC will be investigated clinically at inclusion and a PERKAR1A genotype will be performed.

The primary aim is to assess the clinical manifestations of the CARNEY Complex (CNC) and/or the primary pigmented nodular adrenocortical disease (PPNAD) in patients with CNC, isolated PPNAD or carriers of PRKAR1A and PPNAD1 (PDE11A4) germline mutation (Cohort CNC-PPNAD). In this cohort genotype/phenotype correlation will be studied. A second aim is to determine the frequency of PRKAR1A germline mutation in patients with isolated cardiac myxoma or isolated lentiginosis (Cohort L-MC).

Inclusion Criteria:

CNC group :

• patient with the CARNEY complex (CNC) or the primary pigmented nodular adrenocortical disease (PPNAD) or a germinal mutation of the gene of CARNEY Complex or PPNAD.
• No age criteria
• Inform consent of the patient or the parental authority collected
• Realization of a preliminary medical examination
• Affiliated with a social security system ( profit or having right)

MC-L group :

• Patient with periorificial lentiginosis or cardiac myxoma
• or previous history of periorificial lentiginosis or cardiac myxoma
• age > or = 18 years old
• Realization of a preliminary medical examination
• Affiliated with a social security system ( profit or having right)

Exclusion criteria :

CNC group and MC-L group:

• refusal or incapacity to take part in the study

Consultations